Our strategy includes a patient-centric, comprehensive development program spanning the entire disease continuum from early, localized disease to late-stage, metastatic prostate cancer and includes multiple therapeutic modalities and combination approaches.
We are advancing an industry-leading pipeline and portfolio beginning with a novel agent for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), and two first-in-class registration programs in high-risk localized prostate cancer combining hormonal therapy with radiation and radical prostatectomy. Leveraging the strength of precision medicine, we are also working on therapeutics for patients with prostate cancer who have DNA repair defects where biomarkers help select those most likely to respond to therapy.
Prostate cancer is the second most commonly diagnosed cancer in men and the fourth most common cancer overall.”
We innovate by leveraging novel endpoints to bring patients new transformational therapies. Our approach includes combining therapies in our portfolio, as well as bringing novel compounds and treatment approaches into clinical development, including highly selective targets and multiple platforms and modalities addressing heterogeneity and resistance.
Types of prostate cancer
Localized prostate cancer (LPC)
- 89% of prostate cancers discovered at localized stage when cancer is only inside the prostate gland
- High unmet need in LPC, as some men with high-risk disease experience early metastasis even after aggressive local treatments
- 5-year high-risk LPC PSA relapse-free survival rates range from 55–71%, indicating potential for metastatic relapse
Metastatic castration-sensitive prostate cancer
- Also known as metastatic hormone-sensitive prostate cancer
- Typically responds to testosterone suppression therapy and chemotherapy
Patients with newly identified metastatic disease, either at first diagnosis or following prior local therapy, have a poorer prognosis
Non-metastatic castration-resistant prostate cancer
- No longer responds to hormone treatment and is only found in the prostate
- 90% will develop bone metastases, which can lead to pain, fractures and spinal cord compression
- Median overall survival is less than 5 years
Metastatic castration-resistant prostate cancer
- Has spread to other parts of the body
- No longer responds to a medical or surgical treatment that lowers testosterone
- Median overall survival is less than 3 years in chemotherapy naïve
Prostate cancer by the numbers
- Second most commonly diagnosed cancer in men and the fourth most common cancer overall
- Approximately 1.47 million new cases worldwide
